Pharmacology of Antianginal Drugs

Introduction/Overview

Angina pectoris, characterized by transient chest discomfort due to myocardial ischemia, represents a cardinal manifestation of coronary artery disease. The underlying pathophysiology involves an imbalance between myocardial oxygen supply and demand. Pharmacological management aims to correct this imbalance, alleviate symptoms, improve exercise tolerance, and reduce the risk of adverse cardiovascular events. The selection of antianginal therapy is guided by the specific angina syndrome—stable, unstable, or variant (Prinzmetal’s)—as well as patient comorbidities and hemodynamic status. A thorough understanding of the pharmacology of these agents is therefore fundamental for the rational and effective treatment of ischemic heart disease.

The clinical relevance of antianginal drugs extends beyond symptomatic relief. Effective management can enhance quality of life, reduce hospitalizations, and, for certain drug classes, potentially improve long-term outcomes. The therapeutic approach is often multifaceted, combining lifestyle modification with one or more pharmacological agents from distinct classes to achieve synergistic effects while minimizing adverse reactions.

Learning Objectives

• Classify the major drug groups used in the treatment of angina pectoris and describe their fundamental mechanisms of action at the molecular, cellular, and systemic levels.
• Compare and contrast the pharmacokinetic profiles, including routes of administration, metabolism, and elimination, of organic nitrates, beta-adrenergic antagonists, calcium channel blockers, and other anti-ischemic agents.
• Analyze the clinical applications of each antianginal drug class, distinguishing their roles in stable, unstable, and variant angina, and identify common off-label uses.
• Evaluate the major adverse effect profiles, contraindications, and significant drug-drug interactions associated with antianginal therapies.
• Formulate appropriate therapeutic considerations for special populations, including patients with renal or hepatic impairment, the elderly, and pregnant individuals.

Classification

Antianginal drugs are primarily categorized based on their dominant mechanism for relieving myocardial ischemia. The three principal classes have been the cornerstone of therapy for decades, with newer agents offering alternative or adjunctive pathways.

Major Therapeutic Classes

• Organic Nitrates and Nitrites: This class includes short-acting agents like sublingual nitroglycerin and longer-acting formulations such as isosorbide dinitrate and mononitrate. They function primarily as venodilators.
• Beta-Adrenergic Receptor Antagonists (Beta Blockers): These are subdivided into non-selective (e.g., propranolol, nadolol) and cardioselective (β₁-selective; e.g., atenolol, metoprolol) agents. Some possess intrinsic sympathomimetic activity (e.g., pindolol) or ancillary properties like alpha-blockade (e.g., labetalol, carvedilol).
• Calcium Channel Blockers (CCBs): This heterogeneous class is further divided into:
  • Dihydropyridines (DHPs): Primarily arterial vasodilators (e.g., nifedipine, amlodipine, felodipine).
  • Non-Dihydropyridines: Including phenylalkylamines (e.g., verapamil) and benzothiazepines (e.g., diltiazem), which have more pronounced effects on cardiac conduction and contractility.

Other and Adjunctive Agents

• Late Sodium Current Inhibitor: Ranolazine, which modulates myocardial metabolic activity.
• Potassium Channel Openers: Nicorandil, which possesses both nitrate-like and ATP-sensitive potassium channel opening properties.
• If Channel Inhibitor: Ivabradine, which reduces heart rate by inhibiting the sinoatrial node’s funny current.
• Antiplatelet and Anticoagulant Agents: Crucial in the management of acute coronary syndromes (e.g., aspirin, P2Y₁₂ inhibitors).
• Statins and ACE Inhibitors/ARBs: Used for secondary prevention and modification of cardiovascular risk.

Mechanism of Action

The pharmacodynamic actions of antianginal drugs are unified by their ability to restore the balance between myocardial oxygen delivery and consumption, albeit through distinct and often complementary pathways.

Organic Nitrates

Organic nitrates are prodrugs that require bioconversion to release nitric oxide (NO), which is chemically equivalent to endothelium-derived relaxing factor. This conversion is mediated by mitochondrial aldehyde dehydrogenase (ALDH2), particularly in venous smooth muscle. NO activates soluble guanylyl cyclase, increasing intracellular cyclic guanosine monophosphate (cGMP). Elevated cGMP leads to dephosphorylation of myosin light chains, resulting in smooth muscle relaxation. The predominant venodilation reduces preload (ventricular end-diastolic pressure and volume), which decreases myocardial wall tension, a major determinant of oxygen demand. At higher doses, arterial dilation occurs, reducing afterload. These hemodynamic effects collectively lower myocardial oxygen consumption. In variant angina, nitrates directly dilate epicardial coronary arteries, relieving vasospasm. A significant limitation is the rapid development of tolerance during continuous exposure, linked to oxidative stress, depletion of sulfhydryl groups necessary for NO generation, and neurohormonal activation.

Beta-Adrenergic Antagonists

By competitively blocking β₁-adrenoceptors in the heart, these agents antagonize the effects of catecholamines. The primary anti-ischemic effects are mediated through a reduction in heart rate, contractility, and, during exercise, blood pressure. This triad of effects significantly reduces myocardial oxygen demand. The reduction in heart rate also prolongs diastole, the period of coronary perfusion, thereby potentially enhancing oxygen supply. Non-selective beta-blockers (blocking β₁ and β₂ receptors) may offer no additional antianginal benefit and can cause bronchoconstriction and peripheral vasoconstriction. Agents with intrinsic sympathomimetic activity provide partial agonist activity, which may result in less pronounced bradycardia and are generally less preferred for angina. The antianginal efficacy is closely correlated with the degree of exercise-induced tachycardia suppression.

Calcium Channel Blockers

These agents inhibit the influx of extracellular calcium ions through L-type voltage-gated calcium channels in vascular smooth muscle and cardiac myocytes. The resulting effects are class-dependent.

• Dihydropyridines (e.g., Amlodipine, Nifedipine): Exhibit high vascular selectivity, causing potent arterial vasodilation. This reduces afterload and myocardial oxygen demand. Reflex tachycardia can occur with short-acting formulations, which may be detrimental. They are particularly effective in treating coronary vasospasm.
• Non-Dihydropyridines (Verapamil, Diltiazem): Have more balanced cardiac and vascular effects. They cause moderate vasodilation but also depress sinoatrial node automaticity and atrioventricular node conduction (negative chronotropy and dromotropy) and reduce contractility (negative inotropy). The combined reduction in heart rate, contractility, and afterload lowers oxygen demand. Their vasodilatory action can also increase coronary blood flow.

Other Mechanisms

Ranolazine inhibits the late inward sodium current (I_Na) in cardiomyocytes. During ischemia, this current is enhanced, leading to elevated intracellular sodium, which in turn increases intracellular calcium via the sodium-calcium exchanger. The resulting calcium overload impairs diastolic relaxation, increases wall stress, and elevates oxygen demand. By attenuating this process, ranolazine improves diastolic function and reduces ischemia without significantly affecting heart rate or blood pressure, making it a useful adjunctive agent.

Ivabradine selectively inhibits the I_f (“funny”) current in the sinoatrial node, which is crucial for diastolic depolarization. This results in a pure reduction in heart rate, increasing diastolic perfusion time and decreasing oxygen demand. It lacks effects on contractility or vascular tone.

Nicorandil has a dual mechanism: it acts as a nitrate donor, causing venodilation, and also opens ATP-sensitive potassium (K_ATP) channels in vascular smooth muscle, leading to arterial vasodilation and possibly ischemic preconditioning.

Pharmacokinetics

The pharmacokinetic properties of antianginal drugs dictate their dosing regimens, onset and duration of action, and suitability for specific clinical scenarios.

Organic Nitrates

Nitrates exhibit significant first-pass metabolism, necessitating non-oral routes for rapid effect or alternative formulations. Nitroglycerin is rapidly absorbed sublingually, with onset of action within 1-2 minutes and a duration of 20-30 minutes. Transdermal patches provide steady-state plasma levels for 24 hours but require a daily nitrate-free interval to prevent tolerance. Oral isosorbide dinitrate is extensively metabolized to active metabolites (isosorbide-5-mononitrate and -2-mononitrate); its bioavailability is approximately 20-25%. Isosorbide mononitrate has nearly 100% bioavailability and a longer half-life (≈5 hours), allowing for once- or twice-daily dosing. Nitrates are metabolized by hepatic glutathione-organic nitrate reductase and denitrated enzymes, with inactive metabolites excreted renally.

Beta-Adrenergic Antagonists

Pharmacokinetics vary widely within this class. Propranolol is highly lipophilic, undergoes extensive hepatic metabolism (cytochrome P450 2D6, 1A2), and has a short half-life (3-6 hours), though long-acting formulations exist. Its bioavailability is low and variable due to first-pass effect. Metoprolol is also primarily metabolized by CYP2D6, exhibiting significant interindividual variability. Atenolol and nadolol are hydrophilic, have low protein binding, are primarily excreted unchanged by the kidneys, and have longer half-lives (6-9 hours and 14-24 hours, respectively), permitting once-daily dosing. Dose adjustment is necessary in renal impairment for these agents.

Calcium Channel Blockers

Most CCBs are well absorbed orally but undergo substantial first-pass metabolism. Verapamil bioavailability is 20-35%, with extensive metabolism by CYP3A4; its half-life is 3-7 hours but longer for sustained-release formulations. Diltiazem has a bioavailability of 40-50%, is metabolized by CYP3A4, and has a half-life of 3-4.5 hours. The dihydropyridines show high variability: Nifedipine (immediate-release) has rapid onset and short duration, while Amlodipine has very slow absorption, a bioavailability of 60-65%, and a remarkably long half-life (35-50 hours), allowing for stable 24-hour coverage with once-daily dosing and minimal reflex tachycardia. Most CCBs are highly protein-bound and their metabolism is sensitive to CYP3A4 inhibitors and inducers.

Other Agents

Ranolazine is absorbed slowly, with peak concentration (C_max) at 2-6 hours. It is metabolized mainly by CYP3A4 and, to a lesser extent, CYP2D6. Its half-life is approximately 7 hours, requiring twice-daily administration. Strong CYP3A4 inhibitors are contraindicated due to risk of toxicity. Ivabradine has a bioavailability of 40%, is metabolized by CYP3A4, and has a half-life of about 2 hours in extensive metabolizers, necessitating twice-daily dosing. Nicorandil is well absorbed, has a half-life of about one hour, and is excreted renally.

Therapeutic Uses/Clinical Applications

The application of antianginal drugs is tailored to the specific clinical presentation of ischemic heart disease.

Stable Angina Pectoris

The goal is prevention of anginal episodes and improvement of exercise capacity. First-line therapy typically involves a beta-blocker or a calcium channel blocker. Beta-blockers are often preferred in patients with a history of myocardial infarction or concomitant heart failure with reduced ejection fraction. Calcium channel blockers, particularly dihydropyridines or diltiazem, are alternatives or additions, especially if beta-blockers are contraindicated or ineffective. Long-acting nitrates are used as add-on therapy or for situational prophylaxis (e.g., prior to predictable exertion). Ranolazine and ivabradine are considered as second-line or adjunctive agents when symptoms persist on first-line therapy.

Acute Coronary Syndromes (Unstable Angina/NSTEMI)

In the acute setting, sublingual or intravenous nitrates are used for immediate relief of ongoing ischemia and hypertension. Beta-blockers, initiated orally, are a cornerstone for reducing myocardial oxygen demand and infarct size, provided the patient is hemodynamically stable. Calcium channel blockers (specifically verapamil or diltiazem) may be used if beta-blockers are contraindicated and there is no significant left ventricular dysfunction. The primary pharmacological focus, however, is on antiplatelet agents, anticoagulants, and statins.

Variant (Prinzmetal’s) Angina

This form, caused by coronary artery spasm, is most effectively treated with calcium channel blockers and nitrates. High doses of dihydropyridines or non-dihydropyridines are often required. Beta-blockers, particularly non-selective ones, may be detrimental as they can permit unopposed alpha-adrenergic mediated vasoconstriction.

Other Clinical Applications

• Heart Failure: Certain beta-blockers (bisoprolol, carvedilol, metoprolol succinate) and the CCB amlodipine are used in heart failure with reduced or preserved ejection fraction, often in patients with concomitant angina.
• Arrhythmias: Beta-blockers, verapamil, and diltiazem are used for rate control in atrial fibrillation and for suppressing supraventricular tachycardias.
• Hypertension: Beta-blockers, CCBs, and sometimes nitrates are employed as antihypertensive agents.
• Microvascular Angina: Agents like ranolazine, CCBs, and nitrates may be used, though evidence is less robust.

Adverse Effects

The adverse effect profiles are largely extensions of the drugs’ pharmacological actions.

Organic Nitrates

The most common adverse effects are headache, flushing, and postural hypotension due to vasodilation. Reflex tachycardia may occur. Syncope is a risk, particularly with rapid-acting formulations. Methemoglobinemia is a rare but serious complication with high doses. Chronic use can lead to tolerance, rendering the drug ineffective unless a daily nitrate-free interval (e.g., 10-12 hours) is implemented. Abrupt withdrawal after chronic use may precipitate rebound ischemia.

Beta-Adrenergic Antagonists

Bradycardia, heart block, and negative inotropy can precipitate or exacerbate heart failure. Fatigue, cold extremities, and vivid dreams are common. Bronchoconstriction is a serious concern with non-selective agents in patients with asthma or COPD. Metabolic effects include masking of hypoglycemic symptoms in diabetics and potentially adverse effects on lipid profiles (increased triglycerides, decreased HDL). Abrupt withdrawal can cause rebound tachycardia, hypertension, and worsening angina.

Calcium Channel Blockers

Dihydropyridines frequently cause peripheral edema, headache, flushing, and reflex tachycardia. Gingival hyperplasia is associated with chronic use. Non-dihydropyridines can cause bradycardia, heart block, and constipation (particularly verapamil). Negative inotropy may worsen pre-existing systolic heart failure. All CCBs can cause hypotension.

Other Agents

Ranolazine can cause dizziness, nausea, and constipation. A dose-related prolongation of the QT interval is observed, necessitating caution and avoidance with other QT-prolonging drugs. Ivabradine can cause luminous phenomena (phosphenes), bradycardia, and atrial fibrillation. Nicorandil may cause headache, flushing, and, rarely, oral, intestinal, and perianal ulceration.

Drug Interactions

Significant interactions arise from pharmacodynamic synergism or pharmacokinetic alterations.

Pharmacodynamic Interactions

• Additive Hypotension/Bradycardia: Concomitant use of nitrates, beta-blockers, CCBs, and other antihypertensives can lead to profound hypotension, syncope, or excessive bradycardia.
• Heart Failure Exacerbation: The negative inotropic effects of beta-blockers and non-DHP CCBs can be additive, potentially decompensating heart failure.
• Excessive Bradycardia/Heart Block: The combination of beta-blockers with verapamil or diltiazem significantly increases the risk of severe bradycardia and advanced heart block; this combination is generally contraindicated or used with extreme caution.
• Phosphodiesterase-5 Inhibitors (e.g., Sildenafil): Potentiate the hypotensive effects of nitrates via shared cGMP pathways. This combination is contraindicated due to risk of life-threatening hypotension.

Pharmacokinetic Interactions

• CYP3A4 Interactions: Many CCBs, ranolazine, and ivabradine are substrates of CYP3A4. Strong inhibitors (e.g., ketoconazole, clarithromycin, ritonavir) can dramatically increase their plasma levels, leading to toxicity. Inducers (e.g., rifampin, phenytoin) can reduce efficacy.
• CYP2D6 Interactions: Metoprolol and propranolol metabolism can be inhibited by drugs like fluoxetine and quinidine, increasing their effects.
• Hepatic Blood Flow: Propranolol can reduce hepatic blood flow, altering the clearance of drugs with high extraction ratios (e.g., lidocaine).

Special Considerations

Pregnancy and Lactation

Treatment decisions require careful risk-benefit analysis. Beta-blockers, particularly labetalol and metoprolol, are often considered first-line for angina or hypertension in pregnancy, though they may be associated with fetal bradycardia and growth restriction. Nitrates may be used for acute relief. Most CCBs (especially nifedipine) are also used, but verapamil has been associated with teratogenic effects in animal studies. Ranolazine and ivabradine are not recommended due to lack of safety data. Most antianginals are excreted in breast milk; beta-blockers with high protein binding and short half-lives (e.g., metoprolol) may be preferred during lactation.

Pediatric and Geriatric Considerations

Angina is rare in pediatrics, but beta-blockers may be used for other indications like arrhythmias. In geriatric patients, age-related pharmacokinetic changes are significant: reduced hepatic metabolism, decreased renal clearance, and altered volume of distribution. There is also increased sensitivity to pharmacodynamic effects (e.g., postural hypotension, bradycardia). Dosing should follow a “start low, go slow” principle. The risk of drug interactions is higher due to polypharmacy.

Renal Impairment

Dose adjustment is primarily required for drugs excreted renally in active form. This includes the hydrophilic beta-blockers (atenolol, nadolol, sotalol) and the active metabolites of some agents (e.g., N-acetylprocainamide from procainamide). Most nitrates, lipophilic beta-blockers, CCBs, ranolazine, and ivabradine do not require routine dose adjustment for renal impairment, but caution is advised due to potential metabolite accumulation or increased sensitivity to hypotensive effects.

Hepatic Impairment

Drugs with extensive hepatic metabolism or high first-pass effect require caution. Doses of nitrates, lipophilic beta-blockers (propranolol, metoprolol), and most CCBs may need reduction due to decreased clearance and increased bioavailability. The risk of hypotension and adverse effects is elevated. Ranolazine is contraindicated in patients with cirrhosis due to significant hepatic metabolism.

Summary/Key Points

• Antianginal therapy aims to correct the imbalance between myocardial oxygen supply and demand through distinct pharmacological pathways: reducing preload (nitrates), reducing heart rate and contractility (beta-blockers, non-DHP CCBs, ivabradine), reducing afterload (CCBs, nitrates), and directly dilating coronaries (nitrates, CCBs).
• The three main classes—nitrates, beta-blockers, and calcium channel blockers—form the foundation of treatment, with selection guided by angina type, comorbidities, and hemodynamic profile. Ranolazine and ivabradine serve as important adjunctive or alternative agents.
• Pharmacokinetic properties dictate practical use: sublingual nitroglycerin for acute relief, long-acting formulations for prophylaxis, and agents like amlodipine for stable 24-hour coverage. Awareness of metabolic pathways (CYP3A4, CYP2D6) is crucial for anticipating drug interactions.
• Adverse effects are often mechanism-based: headaches with nitrates, bradycardia with beta-blockers, edema with DHPs, and constipation with verapamil. Serious risks include hypotension, exacerbation of heart failure, and, with specific combinations, life-threatening bradycardia or heart block.
• Critical drug interactions include the contraindicated combination of nitrates with phosphodiesterase-5 inhibitors and the cautious use of beta-blockers with non-dihydropyridine CCBs. CYP3A4 inhibitors can cause significant toxicity with many agents in this class.
• Special populations require tailored approaches: dose reduction in elderly and hepatically impaired patients, renal adjustment for hydrophilic beta-blockers, and careful agent selection in pregnancy and lactation, prioritizing established safety profiles.

Clinical Pearls

• Always instruct patients on the proper use of sublingual nitroglycerin: sit down, administer one tablet every 5 minutes for up to three doses, and seek emergency care if pain persists.
• Implement a daily nitrate-free interval (e.g., overnight) for patients on long-acting nitrate formulations to prevent the development of tolerance.
• When initiating a beta-blocker for angina, titrate the dose to achieve a resting heart rate of 50-60 beats per minute and to blunt exercise-induced tachycardia.
• Avoid abrupt discontinuation of beta-blocker therapy due to the risk of rebound ischemia; a gradual taper over 1-2 weeks is recommended.
• For patients with stable angina and concomitant systolic heart failure, select antianginal agents with proven mortality benefit in heart failure, such as specific beta-blockers (carvedilol, bisoprolol, metoprolol succinate) or amlodipine.
• Consider ranolazine as an adjunct in patients with persistent angina despite standard therapy, particularly if heart rate or blood pressure is already low, as it does not significantly affect these parameters.

References

1. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
2. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
3. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
4. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
5. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
6. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
7. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
8. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.